University of California, Los Angeles

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, Los Angeles sits in the top decile of US sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count).

897 total trials 158 currently recruiting 622 completed early-phase tilt top decile by trial count

University of California, Los Angeles: 897 sponsored US clinical trials, 158 recruiting.

University of California, Los Angeles sponsors 897 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 622 completed. 98 of these trials are in Phase 3-4 (later-stage) and 194 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 17 trials.

Top-decile sponsor footprint

University of California, Los Angeles ranks in the top decile of sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

622 of 679 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

897 total, page 11 of 18

COMPLETED Phase 4

Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine

NCT02505477

TERMINATED NA

Study to Compare Palindrome vs. BioFlo DuraMax Dialysis Catheters

NCT02796300

COMPLETED NA

E-cigarettes, Nicotine Inhaler, and Blood Vessel Function

NCT03072628

COMPLETED NA

Reminder Focused Positive Psychiatry in Adolescents With ADHD and PTSD

NCT04336072

COMPLETED NA

Effectiveness of Changing Dietary Fat on Weight Loss

NCT02953158

COMPLETED NA

Identification and Removal of the Non Palpable Etonogestrel Contraceptive Implant

NCT02986204

COMPLETED Phase 1

Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID

NCT02999984

COMPLETED

Invasive Approach to Model Human Cortex-Basal Ganglia Action-Regulating Networks

NCT03608228

COMPLETED Phase 1

MRA With Feraheme in HHT

NCT02977637

COMPLETED NA

Enhancing Cognitive Training Through Exercise Following a First Schizophrenia Episode

NCT02823041

COMPLETED

Grade Book Game Evaluation Among 6th Grade Students

NCT03039894

COMPLETED NA

Effects of Branch Chain Amino Acids on Glucose Tolerance in Obese Pre-Diabetic Subjects

NCT02684565

COMPLETED Phase 1

Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers

NCT02751359

TERMINATED

Ocular Imaging Study Using Advanced OCT

NCT02827071

COMPLETED Phase 4

Trial of Levomilnacipran in Geriatric Depression

NCT02466958

COMPLETED Phase 4

Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women

NCT02584140

COMPLETED Phase 2

Combining Varenicline and Naltrexone for Smoking Cessation

NCT02698215

TERMINATED NA

Cord Milking Impacts Neurodevelopmental Outcomes in Very Low Birth Weight Infants

NCT02987764

COMPLETED

Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks

NCT03153371

COMPLETED NA

Investigation of an Amino Acid Supplement on Glucose Levels in Obese Subjects

NCT03715010

TERMINATED NA

Thalamic Low Intensity Focused Ultrasound in Brain Injury

NCT02522429

COMPLETED NA

Nanodiamond Modified Gutta Percha (NDGP) Composite for Non-surgical Root Canal Therapy (RCT) Filler Material

NCT02698163

COMPLETED NA

The Impact of Family Financial Support on Cognition

NCT02723318

COMPLETED NA

The Impact of Family Financial Support on Child Health

NCT02770144

COMPLETED NA

Effectiveness of CES on Emotional and Cellular Wellbeing

NCT03369418

COMPLETED NA

The Impact of Family Financial Support on Parental Stress

NCT02723227

COMPLETED NA

The Impact of Family Financial Support on Health Related Quality of Life

NCT02722005

COMPLETED NA

The Impact of Family Financial Support on Parental Mental Health

NCT02723357

COMPLETED NA

H3: Healthy Minds, Healthy Children, Healthy Chicago Project Evaluation

NCT02699814

COMPLETED Phase 4

Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients

NCT02321930

COMPLETED NA

Participatory Messaging in the UCLA Psychiatry Partial Hospitalization and Intensive Outpatient Programs

NCT02708940

COMPLETED NA

Mobile Self-Management of Irritable Bowel Syndrome for Adolescents

NCT03138980

COMPLETED NA

A Behavioral Intervention for Pain Catastrophizing in Primary Dysmenorrhea

NCT02640079

COMPLETED NA

Effectiveness of Peer Navigation and Contingency Management on Retention in HIV Care

NCT02310893

COMPLETED

Phenotyping IBS: Perceptions and Modulations of Visceral Sensations

NCT02693730

COMPLETED NA

Brain Connectivity and Response to Tai Chi in Geriatric Depression

NCT02460666

COMPLETED

Anxiety and Reward Interaction and Prediction of Outcomes in Anorexia Nervosa

NCT02948452

TERMINATED NA

Remote Preconditioning Over Time To Empower Cerebral Tissue

NCT02169739

COMPLETED Phase 1

Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease

NCT02234934

COMPLETED

Imaging Innovations for Placental Assessment in Response to Environmental Pollution (PARENTs)

NCT02786420

COMPLETED NA

Writing About Experiences and Health in Older Adults

NCT02472379

COMPLETED NA

The Effect of Pomegranate on Aging and Inflammation of the Skin

NCT02258776

COMPLETED NA

Augmentation of Brief Habit Reversal Training With D-cycloserine or Placebo

NCT02582515

TERMINATED Phase 1

Abatacept for SLE Arthritis (IM101-330)

NCT02429934

COMPLETED NA

Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex

NCT02687633

COMPLETED NA

A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease

NCT02620488

COMPLETED NA

Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System

NCT02797262

COMPLETED NA

Web-based Preconception Health Education Tool

NCT02529527

COMPLETED NA

Optimizing Exposure Therapy for Anxiety Disorders

NCT04048824

COMPLETED NA

E-cigarettes and Blood Vessel Function

NCT02740595

← Previous Page 11 of 18 Next →

Phase Distribution

PhaseTrial count
Phase 1 112
Phase 2 82
Phase 3 22
Phase 4 76

What is open in the University of California, Los Angeles pipeline

158 recruiting of 897 indexed (18% open); 622 completed (69%).

Phase mix: 98 late (III/IV) vs 194 early (I/II) (early-phase heavy).

Top condition: Depression (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, Los Angeles: open-pipeline peers nationwide

Peers matched on 897 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 5%10%15%20% Total trials Recruiting share University of California, Los AngelesIndiana UniversityHoffmann-La RocheBrigham and Women's HospitalUniversity of Texas Southwestern Medical CenterConvaTecEndologixNational Institute on Deafness and Other Communication Disorders (NIDCD)NICHD Pelvic Floor Disorders Network
University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 897 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this University of California, Los Angeles page

897 registered trials is a research-attention snapshot, not an endorsement of University of California, Los Angeles or any single study.

  • 158 of University of California, Los Angeles's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition University of California, Los Angeles studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, Los Angeles pipeline card: 897 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.